First People's Hospital of Hangzhou — CureCurrent

How to interpret these research links

Connected source records

The exact organization name First People's Hospital of Hangzhou appears in 36 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials36

Recruiting shown4

Roles2

SourceClinicalTrials.gov

Clinical trials

36 shown

Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaNCT07207278 · lead sponsor · 2025-09-01

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLCNCT06718309 · lead sponsor · 2024-04-24

Intradermal Acupuncture as an Adjunct to SSRI Tapering in Major Depressive DisorderNCT07390981 · lead sponsor · 2026-10-01

NOT_YET_RECRUITING

Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung CancerNCT05588206 · lead sponsor · 2022-01-01

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung CancerNCT04749407 · lead sponsor · 2021-02-01

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesNCT04643847 · lead sponsor · 2020-11-30

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCNCT04636593 · lead sponsor · 2020-08-01

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLCNCT05520853 · lead sponsor · 2020-01-20

A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung CancerNCT04757779 · lead sponsor · 2019-12-30

Anlotinib Therapy in Patients With Advanced Lung Cancer.NCT03940404 · lead sponsor · 2019-05-01

ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLCNCT02946216 · lead sponsor · 2016-11-01

A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung CancerNCT02787473 · lead sponsor · 2016-10-01

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI TherapyNCT02788058 · lead sponsor · 2016-05-01

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI TherapyNCT02787447 · lead sponsor · 2016-05-01

EGFR Mutations on ctDNA in Patients With Advanced NSCLCNCT02623257 · lead sponsor · 2016-01-01

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI FailureNCT02418234 · lead sponsor · 2015-03-01

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerNCT01494415 · lead sponsor · 2012-07-01

A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast CancerNCT07304934 · collaborator · 2025-08-01

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast CancerNCT06587789 · collaborator · 2024-01-01

Fertility Decision and Outcomes in Young Women With Breast CancerNCT07804745 · collaborator · 2025-10-15

ACTIVE_NOT_RECRUITING

Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal CongestionNCT07114107 · collaborator · 2025-08-01

NOT_YET_RECRUITING

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 DiabetesNCT07003191 · collaborator · 2023-08-02

ACTIVE_NOT_RECRUITING

B Vitamin Deficiency and Pregnancy ComplicationsNCT05720650 · collaborator · 2023-06-01

Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive DisorderNCT05524519 · collaborator · 2022-11-01

The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive DisorderNCT05720637 · collaborator · 2022-11-01

Acupuncture Therapy Based on Biological Specificity of Acupoints for Major Depressive DisorderNCT05353543 · collaborator · 2022-05-01

Intradermal Needle Therapy for Major Depressive DisorderNCT05352113 · collaborator · 2022-05-01

Acupoint Thermal Radiation Characteristics in Adolescents with MDDNCT06750640 · collaborator · 2022-03-05

The Biological Specificity of Acupoints Between Major Depressive Disorder Patients and Healthy ControlsNCT06114342 · collaborator · 2022-01-10

Efficacy and Safety of Intradermal Acupuncture for Major Depressive DisorderNCT05605002 · collaborator · 2022-01-01

Hangzhou Hospital Staff CohortNCT04910321 · collaborator · 2020-12-30

Patient Report Outcome-Reconstruction and Oncoplastic CohortNCT04030845 · collaborator · 2019-07-01

Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)NCT03125720 · collaborator · 2017-04-14

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer PatientsNCT03123770 · collaborator · 2016-12-01

Voriconazole for IPA in Chinese Patients With COPDNCT02234739 · collaborator · 2014-10-01

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung CancerNCT01404260 · collaborator · 2011-06-01

Drugs studied in this sponsor's trials

11 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing First People's Hospital of Hangzhou as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

docetaxel2

carboplatin1

cisplatin1

cyclophosphamide1

epirubicin1

gefitinib1

pemetrexed1

placebo1

docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial epirubicin RxCUI 3995 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial gefitinib RxCUI 328134 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial pemetrexed RxCUI 68446 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ribociclib RxCUI 1873916 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial thymalfasin RxCUI 38221 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial voriconazole RxCUI 121243 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator19

lead sponsor17

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.